Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

Yamamoto,Hirofumi; Oshiro,Ryota; Nishimura,Junichi; Uemura,Mamoru; Haraguchi,Naotsugu; Hata,Taishi; Takemasa,Ichiro; Mizushima,Tsunekazu; Sekimoto,Mitsugu; Doki,Yuichiro; Mori,Masaki

doi:10.3892/or.2013.2345

May 2013 Volume 29 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May 2013 Volume 29 Issue 5

Full Size Image

Article

Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

Authors:
- Hirofumi Yamamoto
- Ryota Oshiro
- Junichi Nishimura
- Mamoru Uemura
- Naotsugu Haraguchi
- Taishi Hata
- Ichiro Takemasa
- Tsunekazu Mizushima
- Mitsugu Sekimoto
- Yuichiro Doki
- Masaki Mori
View Affiliations / Copyright

Affiliations: Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan, National Hospital Organization, Osaka National Hospital, Osaka, Japan
Pages: 1751-1755
|
Published online on: March 13, 2013

https://doi.org/10.3892/or.2013.2345
Expand metrics +

Abstract

Intra-abdominal desmoid tumor is a life-threatening disease. Studies have shown that dacarbazine (DTIC)-doxorubicin (DOX) (D-D) therapy is the most effective treatment. However, myelosuppression is a major problem, and cardiac muscle disorders due to DOX limit the number of administration cycles, whereas it usually requires a long time to achieve tumor shrinkage. To resolve these issues, we introduced low-dose D-D therapy to 3 patients employing 50 mg/m2 DOX and 600-700 mg/m2 DTIC per cycle, which permits repeated administration cycles up to 10-11 times. Case 1 was a 23-year-old female with a sporadic recurrent mesenterium desmoid tumor located in the pelvis (maximum diameter, 8 cm). Cases 2 and 3 were a 33-year-old female and a 36-year-old male. Both patients had intra-abdominal mesenterium desmoid tumors (maximum diameter 9.6 and 9.0 cm, respectively) that were generated after proctocolectomy due to familial adenomatous polyposis. No severe adverse events occurred during the therapy. With the aid of sulindac and tamoxifen after low-dose D-D therapy, the first two patients achieved a complete response, and the third patient achieved a partial response and awaits further tumor shrinkage. Our experience indicates that low-dose DT-D therapy is a safe and effective regimen for patients with intra-abdominal desmoid tumors.

View Figures

View References

1	de Bree E, Keus R, Melissas J, Tsiftsis D and van Coevorden F: Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther. 9:525–535. 2009.PubMed/NCBI
2	Berri RN, Baumann DP, Madewell JE, Lazar A and Pollock RE: Desmoid tumor: current multidisciplinary approaches. Ann Plast Surg. 67:551–564. 2011. View Article : Google Scholar : PubMed/NCBI
3	Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, et al: Desmoid tumors in familial adenomatous polyposis. Gut. 35:377–381. 1994. View Article : Google Scholar : PubMed/NCBI
4	Clark SK and Phillips RK: Desmoids in familial adenomatous polyposis. Br J Surg. 83:1494–1504. 1996. View Article : Google Scholar : PubMed/NCBI
5	Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC and McGannan E: Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum. 33:639–642. 1990. View Article : Google Scholar : PubMed/NCBI
6	Clark SK, Neale KF, Landgrebe JC and Phillips RK: Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 86:1185–1189. 1999. View Article : Google Scholar : PubMed/NCBI
7	Heiskanen I and Jarvinen HJ: Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis. 11:157–162. 1996. View Article : Google Scholar : PubMed/NCBI
8	Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, et al: Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 24:102–105. 2006. View Article : Google Scholar : PubMed/NCBI
9	Lynch HT, Fitzgibbons R Jr, Chong S, Cavalieri J, Lynch J, Wallace F, et al: Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner’s syndrome. Dis Colon Rectum. 37:260–267. 1994.PubMed/NCBI
10	Patel SR, Evans HL and Benjamin RS: Combination chemotherapy in adult desmoid tumors. Cancer. 72:3244–3247. 1993. View Article : Google Scholar : PubMed/NCBI
11	Poritz LS, Blackstein M, Berk T, Gallinger S, McLeod RS and Cohen Z: Extended follow-up of patients treated with cytotoxic chemotherapy for intra-abdominal desmoid tumors. Dis Colon Rectum. 44:1268–1273. 2001. View Article : Google Scholar : PubMed/NCBI
12	Ezumi K, Yamamoto H, Takemasa I, Nomura M, Ikeda M, Sekimoto M and Monden M: Dacarbazine-doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case. Jpn J Clin Oncol. 38:222–226. 2008. View Article : Google Scholar
13	Gottlieb JA, Benjamin RS, Baker LH, O’Bryan RM, Sinkovics JG, Hoogstraten B, et al: Role of DTIC (NSC-45388) in the chemotherapy of sarcoma. Cancer Treat Rep. 60:199–203. 1976.PubMed/NCBI
14	Gottieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP Jr, Sinkovics JG, et al: Chemotherapy of sarcoma with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer. 30:1632–1638. 1972. View Article : Google Scholar : PubMed/NCBI
15	CTCAE v3.0 and v4.0 provided by the National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
16	Nakada I, Ubukata H, Goto Y, Watanabe Y, Sato S, Tabuchi T, et al: Prednisolone therapy for intra-abdominal desmoid tumors in a patient with familial adenomatous polyposis. J Gastroenterol. 32:255–259. 1997. View Article : Google Scholar : PubMed/NCBI
17	Bauernhofer T, Stoger H, Schmid M, Smola M, Gurtl-Lackner B, Hofler G, et al: Sequential treatment of recurrent mesenteric desmoid tumor. Cancer. 77:1061–1065. 1996. View Article : Google Scholar : PubMed/NCBI
18	Kono T, Tomita I, Chisato N, Matsuda M, Kakisaka A and Kasai S: Successful low-dose chemotherapy using vinblastine and methotrexate for the treatment of an ileoanal pouch mesenteric desmoid tumor: report of case. Dis Colon Rectum. 47:246–249. 2004. View Article : Google Scholar : PubMed/NCBI
19	Weiss AJ, Horowiz S and Lackman RD: Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol. 22:193–195. 1999. View Article : Google Scholar : PubMed/NCBI
20	Okuno SH and Edmonson JH: Combination chemotherapy for desmoid tumors. Cancer. 97:134–135. 2003. View Article : Google Scholar
21	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
22	Hansmann A, Adolph C, Vogel T, Unger A and Moeslein G: High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 100:612–620. 2004. View Article : Google Scholar : PubMed/NCBI
23	Patel SR and Benjamin RS: Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol. 24:11–12. 2006. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Low-dose dacarbazine-doxorubicin therapy against intra-abdominal desmoid tumors

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles